



Hôpital général juif
Jewish General Hospital



McGill

DEPARTMENT OF MEDICINE

ANNUAL REPORT

2010 -2011

**Submitted by
Dr. Ernesto L. Schiffrin
Physician-in-Chief**

DEPARTMENT OF MEDICINE - JEWISH GENERAL HOSPITAL

2010-2011

TABLE OF CONTENTS

- 1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES**
- 2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS**
- 3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS**
- 4. EXTERNAL RESEARCH GRANTS & AWARDS**
- 5. NEW HONORS, AWARDS AND APPOINTMENTS
(SEE APPENDIX A)**
- 6. PUBLICATIONS**
- 7. APPENDIX A.DIVISIONAL REPORTS**
 - 1. Division of Allergy and Clinical Immunology**
 - 2. Division of Cardiology**
 - 3. Division of Dermatology**
 - 4. Division of Endocrinology**
 - 5. Division of Gastroenterology**
 - 6. Division of Genetics**
 - 7. Division of Geriatric Medicine**
 - 8. Division of Hematology-Oncology**
 - 9. Division of Infectious Diseases**
 - 10. Division of Internal Medicine**
 - 11. Division of Medical Biochemistry**
 - 12. Division of Nephrology**
 - 13. Pulmonary Division**
 - 14. Division of Rheumatology**
 - 15. Division of Clinical Epidemiology**

1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES

1.1 ACADEMIC HIGHLIGHTS

I. Introduction

The Department continues to provide excellent clinical care and teaching as well as carry out substantial translational, clinical and epidemiological research which attracts new recruits to the JGH. Although recruitment is limited by government restrictions of the “effectifs médicaux”, we have managed to recruit during the year July 2010-June 2011 five full-time members and four associate members. Potential and confirmed GFT-H recruits as well as changes in staffing are listed below.

Our research activities have been supported by both external funding agencies and by our own Clinical Research Awards.

The progress and challenges of the Department during this last academic year are summarized below.

Faculty

A. Recruits

The following physicians have been recruited into the Department:

GFT members:

Dermatology - Dr. Osama Roshdy (September 2010) Professeur sélectionné

Hematology - Dr. Nathalie Johnson (July 2010)

Pulmonary - Dr. Lama Sakr (January 2011)

Rheumatology - Dr. Sabrina Fallovolita (May 2010)

Rheumatology - Dr. Geneviève Gyger (January 2011)

Associate Members:

Cardiology - Dr. Gizelle Popradi (July 2011)

Geriatric Medicine - Dr. Francine Gaba Idamey (June 2010)

Geriatric Medicine - Dr. Francine Larente (June 2010)

Internal Medicine - Dr. Jennifer Nguyen (August 2010)

2011-2013:

Cardiology - Dr. Jonathan Afilalo (July 2013)

Cardiology - Dr. Annabel Chen-Tournoux (July 2011)

Cardiology - Dr. Vartan Mardigyan (July 2011)

Endocrinology - Dr. Oriana Hoi Yun Yu (July 2012)

Geriatric Medicine - Dr. Isabelle Vedel (Associate Member) (July 2011)
Geriatric Medicine - Dr. Elise Levinoff (July 2013)
Hematology - Dr. François Mercier (July 2013)
Hematology – Dr. Cristiano Ferrario (July 2012)
Internal Medicine / ICU - Dr. Jed Lipes (July 2011)
Nephrology - Dr. Marie Briet (July 2012) Professeur sélectionné
Pulmonary - Dr. Deborah Assayag (July 2013)
Pulmonary - Dr. Nathalie Saad (July 2012)

B. Changes of Status

The following changes in staffing are noted:

Cardiology:

- Dr. Kim Boutet resigned as Associate Member in May 2011.
- Dr. Sven Wassmann resigned from the JGH in September 2010.

Endocrinology

- Dr. Amnon Kahn passed away in November 2010.

Internal Medicine:

- Dr. Michael Gold passed away in April 2011.

Pulmonary

- Dr. Joel Fox resigned as full-time member in May 2010 to become a consultant.

Rheumatology

- Dr. Morton Kapusta resigned as full-time member in May 2010.

C. Promotions

Dr. Andrew Hirsch, whose principal academic interest is pulmonary hypertension and thromboembolic disease, **Dr. Stéphanie Lehoux**, who holds the Canada Research Chair in Cardiovascular Physiology and is investigating the fundamental biology of major cardiovascular diseases including hypertension and atherosclerosis, **Dr. Chen Liang**, whose research is aimed at elucidating the molecular events that take place during the assembly process of human immunodeficiency virus type 1 (HIV-1), **Dr. Igal Sebag** whose work is focused on clinical and research applications of advanced techniques in echocardiography, **Dr. Michael Tamilia**, whose research centers on parathyroid disorders, thyroid tumors and thyroid cancer and **Dr. Marc Tischkowitz**, whose work focuses on the molecular genetics of breast cancer and other common cancers, were promoted from Assistant to Associate professor. Besides, **Dr. Lehoux**, **Dr. Liang** and **Dr. Tischkowitz** were granted tenure.

II. Clinical Activities

- 1) The Clinical Teaching units (CTU's) have been downsized. The strategy of a ratio system has been adopted because it creates less non-CTU beds throughout the academic year. However, when a CTU team is short-staffed by residents the beds default to the attending physician. In the event that this represents too excessive a workload for the physician he/she must secure a "buddy" to help out.
- 2) The Flex Unit remains at the end of the hall on 2M and a new nursing station has been created to serve these beds. There continues to be a census of 12 patients on this unit. The criteria for transfer to this unit include medical stability and discharge arrangements that are pending.
- 3) Renovations will be made to the rest of 2M and the former MHA to accommodate GI lab functions while the actual GI lab undergoes renovations.
- 4) Plans are in place to create an 8-bed unit to serve interventional radiology where patients will be monitored post-procedures and may also receive peri-procedure, hydration, medications, etc.
- 5) The Neurology Unit has been functioning on 4W where neurologists are providing primary care for the first time in many years. There is an average of approx. 12 patients on this service.
- 6) There have been substantial problems with Program 68 with many patients far exceeding the promised 72-hour time frame before transfer to a chronic care facility. Due to manpower limitation, Geriatrics is no longer the sole arbiter of Program 68 eligibility and CTMSP paperwork.
- 7) There have significant challenges with C. difficile outbreaks in the past few months.
- 8) Pavilion K is on schedule.
- 9) There is a major initiative developing to decrease ER congestion sanctioned by the Minister. There are financial incentives and prestige to be garnered if the hospital can deliver tangible results. We will be initiating some novel changes to reduce ER congestion and we will require the support and cooperation of the membership. This is part of the Transformational Change initiative initiated in the hospital by the CEO, Dr. Hartley Stern, and led by Dr. Lorrie Rosenberg and Ms. Lynn McVey. The Department is actively involved in this initiative with the objective of improving the patient experience and accelerating flow of patients out of the ER, to either home, other institutions or wards. The main goal is a reduction of length of stay, waiting times and unnecessary diagnostic or therapeutic procedures.

The clinical activities of the individual Divisions are summarized in the Divisional reports which are attached.

III. Teaching Activities

The Department continues its role in the teaching of both undergraduate medical students and resident physicians in general medicine and the subspecialties. Our members' dedication to teaching is well known and much appreciated by both medical students and residents. The Department is grateful to Dr. Elizov for her dedicated services as Director of Postgraduate Medical Education from July 2005 to June 2011, and welcomes Dr. Ruxandra Bunea as the new Director as of July 1, 2011.

Within the Department, the following staff and residents received awards:

Dr. Ernesto L. Schiffrin received the 2010 Bjorn Folkow Award and Lecture of the European Society of Hypertension in recognition of his contribution to hypertension research. Dr. Schiffrin presented the lecture during the plenary session in Oslo on June 19th, 2010. The Bjorn Folkow Award has been established since 1987 by the European Society of Hypertension with the collaboration of AstraZeneca in recognition of the contribution made by Bjorn Folkow to cardiovascular physiology and pathophysiology. The award is given to a person or persons who have carried out important original research on the pathogenesis of hypertension.

Dr. Ernesto L. Schiffrin was appointed Member of the Order of Canada on June 30, 2010 for his contributions to the study of hypertension, notably through his research on the mechanisms underlying high blood pressure, as well as for his leadership roles in scientific committees and societies.

In 2010 the Board of Governors of the Jewish General hospital selected Dr. Ernesto L. Schiffrin as the recipient of the 2010 Award for Excellence in Basic Research.

In June 2011, Dr. Michelle Elizov, Assistant Professor in the Division of General Internal Medicine and Site Director of the McGill Core Internal Medicine Residency Training Program at the JGH, was presented with the Faculty Honour for Educational Excellence Award in recognition of her outstanding contributions to teaching in the Faculty of Medicine.

Dr. Avshi Leibowitz was the first recipient and Dr. Avi Shimony the second recipient of the Azrieli Fellowship. This fellowship provides opportunities of passing clinical, academic and research excellence as well as new approaches to medical diagnosis, treatment or research to young physicians and scientists of Israel in Canadian academic centers.

Dr. Amjad Al Rajhi received the Dave Feder award. This award is presented to the resident who practices medicine with most compassion and sensitivity, displays kindness, respect and camaraderie towards colleagues and educators and carries a positive outlook enabling him/her to enjoy a meaningful balanced life beyond his/her profession.

Dr. Pernilla D'Souza was the recipient of the Sheldon Zemelman Memorial Award given to for academic excellence and outstanding contribution to patient care.

Dr. Michael Palumbo received the Dr. Allen Spanier Internal Medicine Award. This award is given to the resident who exhibits an enduring passion for the practice of medicine, through the enjoyment of solving challenges of patient care and sharing solutions with others, while maintaining a high level of professionalism.

Dr. Bennett Haynen was the recipient of the Medical Resident Research Award. This award is given to the medical resident who has achieved excellence with regard to intellectual curiosity, initiative, originality and accomplishment in medical research performed during residency.

Dr. Sharon Nessim was voted as Teacher of the Year by the residents.

In 2010-2011 we recruited into our teaching program 15 R3, 13 R2, and 12 R1 housestaff and 9 other program R1 residents. There were two Chief Residents, Dr. Dan Liberman and Dr. Michel Palumbo (July 2010-June 2011).

Grand Rounds: Of the 35 Grand Rounds given by the Department 12 featured speakers from outside the JGH, of whom 6 were from outside Quebec (see attached list).

Divisional Rounds: In addition to the above each Division manages its own teaching and research rounds as summarized in the attached reports.

IV. Research

The Department has had a Clinical Research Award Program since 2007 in order to support and compensate full-time members of the Department involved in clinical research activities. The awards to the 2010 recipients, Drs. Jason Agulnik, Mark Blostein, Nessim Sharon, Christina Greenaway Tina Kader, Mark Miller, Lawrence Rudski, Sarit Assouline, Murray Baron and Morris Schweitzer, were renewed for an additional year in light of their productivity in their fields. The 2011 recipients of this award are Drs. M. Elizov, G. Gyger, N. Hilzenrat, L. Sakr, R. Sheppard and G. Tagalakakis. The Department now supports 16 research projects by GFT-H staff.

For 2010-2011, 11 Departmental members are recipients of prestigious Career Awards, Fellowship Awards or Research Chairs from various granting agencies, totaling \$532 501.

A detailed survey of research activities of the departmental members as indicated below for the period April 1, 2010 to March 31, 2011 is attached.

\$ 1,152,528	Clinical Investigator (including PhD) salary awards
\$18,837,543	Competitive Operating Grants (excluding associate members)
\$ 4,720,080	Contracts from Industry
\$ 168,000	Department of Medicine Clinical Research Awards
\$24,878,151	TOTAL
\$	Postgraduate Fellows
\$ 3,532,603	Endowments & other
\$28,410,754	GRAND TOTAL

In the calendar year 2010, departmental members produced 314 peer reviewed original publications (excluding abstracts, reports, and other articles).

V. Departmental Activities

The Department continues to reinforce democratic and transparent management in all areas.

VI. MUHC and McGill

Our relationship with the MUHC has been characterized by collaboration and collegiality. Our commitment to excellence in teaching at both the undergraduate and postgraduate level continues to be valued by McGill University

Within the hospital progress has been made. The Division of Gastroenterology will move into new facilities in the near future while the current location undergoes renovations. The Cardiovascular Prevention Centre provided the facility for the CARTAGENE project during the past year and a half. This project's goal is the genotyping, and the phenotyping of certain characteristics, of the Quebec population.,. The Department continues to work towards maintaining its academic mission with improved staffing and resource allocation.

The Department gratefully recognizes the support of the Hospital Administration in its recruitment efforts.

1.2 OBJECTIVES AND PRIORITIES

Within the province, the Department of Medicine continues to play a key role with Dr. Ernesto L. Schiffrin's term as President of "la Table régionale des chefs de département de médecine spécialisée de l'Île de Montréal" and as President of the Société québécoise d'hypertension artérielle up until January 2011, and internationally as Vice-President and President-Elect of the International Society of Hypertension.

The Department is actively pursuing to recruit an international leader in aging. The chosen candidate will be offered the Kaufman Chair previously held by Dr. Howard Bergman.

We remain dedicated to ensure that the department continues to provide the excellent care to the patients of the hospital for which it is renowned, while at the same time maintaining its goals of excellence in teaching. The recruitment of highly qualified and competitive physician scientists has reinforced the research capacity of the department and has had a transformative effect on the ability of the hospital to serve as a translational science center. It has been challenging to provide conditions that are competitive with the best North American centers due to constraints in funding for personal support, operating monies and up-to-date equipment, as well as difficulties in ensuring adequate space allocation and support services. Despite these difficulties and constraints, we have been successful as can be seen above in already recruiting a considerable group of young physician-educators and physician-scientists in the areas of internal medicine, cardiology, endocrinology, hematology, pulmonary medicine, rheumatology and nephrology, all

of who have a good chance of success in scientific competition for the scarce resources currently available locally, provincially and nationally. We have put in place a program that will also help support the research by GFT-H physicians. The second Department of Medicine Doctors' Gala on November 18, 2010 was a great success both from the financial and cooperation point of view thanks to the efforts of departmental staff and the executive team comprising of Mr. A. Rubin, Ms. Annette Goldman and their excellent work in raising the profile and funds for the Department of Medicine and provide it with means to achieve the objectives of high quality and safe care, excellent teaching and a highly competitive clinical and translational research environment despite current bureaucratic and funding constraints.

Respectfully submitted,

Ernesto L. Schiffrin, CM, MD, PhD, FRSC, FRCPC
Physician-in-Chief

2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS

September 13	The New Cancer Endocrinology	Michael Pollak, MD
September 20	Update in Osteoporosis: New Therapeutics for Old Bones	Andrew C. Karaplis, MD, PhD
September 27	The Eight Cognitive Syndromes Often Missed by Physicians	Howard Chertkow, MD
October 4	McGill/Merck-Schering Lipid Lectureship 2010: Management of Atherogenic Dyslipidemia of the Metabolic Syndrome	Ronald M. Krauss, MD, University of California, San Francisco
October 18	Right Ventricular Dysfunction in Cardiac Surgery	André Denault, MD, CHUM
October 25	Lung Cancer: New Advances	Jason Agulnik, MD
November 1	Quality Program Annual Patient Safety Week: Patient Safety and Acute Care Medicine: Lessons for the Future, Insights from the past	Denny P. Laporta MD
November 8	Rare Forms of Diabetes: What Can Genetics Teach Us about the Endocrine Pancreas?	Constantin Polychronakos MD, MUHC
November 15	IL-17 Activates the Endothelium Increasing Adhesion of Circulating Tumour Cells; Potential Implication for Metastasis Formation	Simon Rousseau PhD, MUHC
November 22	Diffuse Large B Cell Lymphoma: One Diagnosis, Many Diseases	Nathalie A. Johnson, MD, PhD
November 29	Endoscopic Ultrasound at the JGH	Jonathan Wyse, MD
December 6	23rd Annual Nachum & Bertha Mizne Memorial Lecture: Fatty Liver: a Silent Target of the Obesity Epidemic	Nir Hilzenrat, MD
December 13	Acute Respiratory Distress Syndrome (ARDS): An Update	Paul Warshawsky, MD
January 10	Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: the JGH Experience	Eman Abdou, MD, MSc & Martin Gyger, MD
January 17	Update on Recent Clinical Trials: Do Results Support Conclusions?	Jan A. Staessen, MD, PhD, Leuven, Belgium
January 24	Infectious Diseases & Immunodeficiencies: Where the Rubber of Immunology Hits the Road of Life	Donald C. Vinh, MD, MUHC
January 31	Updates in Interventional Cardiology: Focus on Coronary Occlusions	Dominique Joyal, MD
February 7	Fifteenth Annual Humanization of Care Awareness Program: Clinician-patient Communication to Enhance Health Outcomes	Michele Nanchoff-Glatt, PhD, University of Calgary
February 14	Assessment of Quality of Care Given to Vulnerable Elders on Medical Teaching Wards: Challenges in Application of the "Acove" Quality Indicators	Catherine Talbot-Hamon, MD, Internal Medicine Resident, McGill University-JGH
February 21	Postgraduate Internal Medicine Residency Training: Future Directions and Challenges	Michelle Elizov, MD & Vicky Tagalakakis, MD
February 28	Pulmonary Arterial Hypertension - Emerging Therapeutic Targets	David Langleben, MD
March 7	An Evidence-based Approach to Improving Hospital Care of Older Persons	Steven R. Counsell, MD, Indiana University School of Medicine, Indianapolis
March 14	Dicer1: the Link Between Micrnas, Multinodular Goitre and Rare Tumors	Marc Tischkowitz, MD, PhD
March 21	Virtual Reality: a New Realm in Rehabilitation	Joyce Fung, PhD, MUHC
March 28	Quality and Risk Management Program: Rediscovering Lost Values	Aidan Halligan, MA, MD, London, UK
April 4	Cognitive Impairment in Type 2 Diabetes: Relevant and Related Findings from the Accord Diabetes Trial	Jeff Williamson, MD, Wake Forest University School of Medicine, NC
April 11	Rhinitis/sinusitis: How Do We Treat Upper Airway Disorders	Saul Frenkiel, MD & Peter Small, MD
April 18	Pulmonary Clinical Pathological Conference	Guilherme Brandao, MD, Andrew Hirsch, MD & Mark Palayew, MD
May 2	New Data in Cutaneous Melanoma: a Light in the Dark	Alan Spatz, MD
May 9	Capillaroscopy in Rheumatic Diseases	Geneviève Gyger, MD
May 16	The New Minimum: How Revised Tri-council Standards for Research Ethics Affect JGH Researchers	Carolyn Ells, PhD
May 30	Life-long Learning and the New Mainport System	Sam Daniel, MD, MUHC
June 6	Opportunity Knocks: Early Physiotherapy And Spontaneous Awakening Trials In Critically Ill Patients	Amjad Al-Rajhi Third Year Internal Medicine Resident, McGill University-JGH
June 13	Erythropoietin Use in Kidney Disease: Intent to Treat	Gershon Frisch, MD
June 20	Advances in the Treatment of Peritoneal Carcinomatosis: Hyperthermic Intraperitoneal Chemotherapy (Hipec) Tsafirir Vanounou, MD, MBA	

3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS

A. REPORT OF UNDERGRADUATE TEACHING - JUNE 2011

There continues to be exciting progress in the undergraduate education program.

1. Clerkship & LCME/CACMS Accreditation Issues

- The current structure has each student doing 4 weeks of either 7W or 7NW, 2 weeks of CCU/2NE, 2 weeks of ER Consults, and a weekly outpatient clinic. The JGH rotation generally receives excellent evaluations.
- The oral examination in clerkship has been eliminated for the 2011-2012 year. Instead, all students will be required to complete one observed focused history and one observed focused physical examination. These are now part of the logs of minimal clinical exposures that students must complete and log in one45 before the end of the rotation. If they are having difficulty seeing these cases, they are supposed to discuss with you so that it can be arranged.
- McGill Faculty of Medicine accreditation standards also require:
 - i. Face-to-face specific, constructive, and individual midway feedback from the attending: This must occur after 2 weeks and at the end of the 4 week rotation on 7W & 7NW, and at the end of each week and at the end of the 2 week rotation in CCU & ER Consults.
 - ii. Adherence to the workload policy: Students can work no more than 60 hours per week excluding on-call (i.e. leave by 8 pm or ideally 6 p.m. when not on-call). When on-call, they must leave by 10 pm. There is no post-call day.
 - iii. The core clerkship lecture series: The sessions are going very well thanks to our dedicated teachers from across many divisions. The objectives for these sessions are available on WebCT and are sent out by Malka when requesting participation from each Division in the teaching sessions. For students who miss the sessions, the alternatives are available on WebCT.
 - iv. Prompt evaluation of students by attendings in the One45 system: Final evaluations must be submitted promptly to the Faculty of Medicine. This requires that your clinical evaluations be completed within 2 weeks of the end of your time with time on the clinical service.
 - v. Orientation of the faculty members to the structure and objectives of the rotation: Dr. MacNamara and Dr. Cummings have developed a pocket card that will be distributed to all attendings at the beginning of their CTU weeks. This contains information about the learning objectives for the clerkship, as well as accreditation-related issues of mistreatment, midway feedback, and the workload policy.

- vi. Information to faculty members about mistreatment: In the 2009-2010 academic year, 45 clerks were assigned to the JGH for Internal Medicine. Of these students, 4 reported mistreatment. So far in 2010-2011, we have had 2/35 clerks in Internal Medicine at the JGH report mistreatment.
- New clinical evaluation forms and guidelines for clinical assessment have been developed at the level of the Faculty of Medicine to be used in all clerkship rotations in all disciplines at all training sites starting 2011-2012.

2. Professional skills (ICS)

- The Professional Skills (ICS) course in January 2011 was very successful. The reduction to 4 students rather than 6 students per group was better for the students and the tutors and we will do the same in January 2012. There are no major changes to the course predicted for January 2012.

3. IIM

- For 2011 the course remains very successful at the JGH. Thanks to the participation of physicians from across the Department of Medicine, the tutors and the teaching sessions remain very highly rated. There are no major changes to the course predicted for 2012.

The Undergraduate Education is grateful to all staff for their enthusiasm, ongoing commitment to teaching and dedication to medical students.

Respectfully,

Drs. B. Cummings & E. MacNamara
Director and Associate Director of Undergraduate Education

B. POSTGRADUATE TEACHING REPORT - JUNE 2011

Resident Numbers

There will be 12 incoming R1's in 2011-2012 resulting in a total of 37 residents over the three years.

The chief medical residents for the 2011-2012 academic year will be John Angelopoulos and Mathew Hannouche. Many thanks to the outgoing chiefs Dan Liberman and Michael Palumbo for their hard work and dedication to improving all aspects of the program.

Program Changes

Night Float

Since July 2010, there has been a night float system in place for coverage of the 7W and 7NW CTUs and the non-teaching medical patients. A consistent team is covering by shift work 10 of 14 nights in a 2-week and deals with all emergencies and any potential admissions not done during the day.

Overall, the feedback from residents and attendings has been positive. While the rotation itself can be difficult, the residents recognize the very positive trade-off of never being post-call as a senior on the wards and the continuity this provides to the patients has been welcome by all.

Issues we are still working on are how to provide staff feedback to this night float team, as well as more formal AM teaching or feedback around management decisions made by the night float team.

To help address some of the concerns about increased errors due to increased number of handovers, there was a workshop for the residents on safe handover practices that was overall well appreciated and will likely be repeated annually.

Academic ½ Day

The Thursday afternoon videoconferenced lecture series for the residents has been well appreciated and seem to work well. Residents consistently report that they are being released appropriately from service to attend these rounds.

The curriculum for this series undergoes regular review at the McGill Training Committee level.

CTU size

Much discussion has occurred around this topic over the course of the year. Our CTUs were much larger than those at the MUHC and this was cause for concern about service to education ratios across the 3 training sites.

Ultimately, it was decided that the CTU size would be proportional to the number of patients-to-resident (student) maximums that had been established and agreed upon at the McGill level. The excess numbers of patients would be looked after the attendings directly and would necessitate a "buddy system in which attendings would pair up to assist each other so as not to make the

balance of patient care, supervision and teaching more manageable and appropriate. This was approved at the Policy Committee.

Looking ahead

Royal College accreditation for the McGill Internal Medicine Training Program will occur in March of 2012.

The biggest issue that still remains and can have a significant impact on our accreditation status is that of the ER consult service. While many positive changes have been made, and the general feedback from out-going residents is that this remains one of the most useful rotations of their training, there are still several issues that affect morale of the residents enough to negatively impact the perception of the rotation, and thus to negatively impact the accreditation process as a result.

Change to the template of the rotation to three 8-hour shifts from two 12-hour ones, recruitment of full-time nursing help (Nurse Practitioner or Clinical Nurse Specialist initially) and the number of patients, that the team is responsible for are being explored.

End of Year Party

The end of year party was held on June 2nd at Le Living Room. It was well attended and staffs were appreciative of the residents' contribution to the Department of Medicine.

Respectfully submitted,

Michelle Elizov, MD
Director, Postgraduate Medical Education

GENERAL INTERNAL MEDICINE HOUSESTAFF LIST 2010-2011

CHIEF RESIDENTS

Dr. Michael Palumbo (July 1 – Dec 31, 2010)

Dr. Dan Liberman (Jan 1 – June 30, 2011)

R3

Dr. Waleed Al-Harbi
Dr. Amjad Al-Rajhi
Dr. Ramy Antar
Dr. Pernilla D'Souza
Dr. Jennifer Friedmann (end date period 5)
Dr. Philippe Le
Dr. Elise Levinoff (end date period 11)
Dr. Dan Liberman
Dr. Savoula Nickas
Dr. Michael Palumbo
Dr. Mandana Rasti
Dr. Nadia Sant
Dr. Line Srour
Dr. David Wasserman
Dr. Marie-Diba Eid

R2

Dr. Daniel Amzallag
Dr. John Angelopoulos
Dr. Marie-Pierre Dallaire
Dr. Alaa Dekis
Dr. Oscar Diaz Noriega
Dr. Michael Goldfarb
Dr. Mathew Hannouche
Dr. Daniel Kaud
Dr. Nessrine Sabri
Dr. Catherine Talbot-Hamon
Dr. Bennett Haynen
Dr. Ahd Al-Khunaizi
Dr. Yousif Bahbahani

R1

Dr. Khalid Al Johani
Dr. Kevin Chan Tai Kong
Dr. Emilie Chan
Dr. Yen-I Chen
Dr. Kaethe Clarke
Dr. Yannick Emond
Dr. Anna Khananian
Dr. Darius Lazarus
Dr. Yidan Lu
Dr. Brent Ohata
Dr. Kristin Popiel
Dr. Tanya Skamene

OTHER PROGRAMS

Dr. Rayan Abdulghani Alkhoidair
(Dermatolgoy)
Dr. Faisal Mohammed Al-Subhi
(Dermatology)
Dr. Mihaylova Yanka (Med Biochem)
Dr. Arnold Radu (Diag RX 1-6)
Dr. Joseph Peltz (Diag RX 7-11)
Dr. Hanni Bouma (Neuro)
Dr. Alina Webber (Neuro)
Dr. Youjia Shen (Ophth)
Dr. Ahmad Alali (Ophth)

4. EXTERNAL RESEARCH GRANTS & AWARDS

A. Career Awards - July 2010 - June 2011 (Clinician-Scientists)

Name	Agency	Expiry Date	Amount
ASSOULINE, Dr. S.	FRSQ	June 30, 2014	33 708
EISENBERG, Dr. M.	FRSQ	June 30, 2012	30 000
GREENAWAY, Dr. C.	FRSQ	June 30, 2013	40 832
HUDSON, Dr. M.	CIHR	June 30, 2012	60 000
JOHNSON, Dr. N.	Canada Research Chair	June 30, 2016	16 667
KAHN, Dr. S.	FRSQ	June 30, 2013	30 000
KARAPLIS, Dr. A.	McGILL DAWSON	June 30, 2012	10 000
RICHARDS, B.	CIHR	June 30, 2012	140 000
SCHIFFRIN, Dr. E.	Canada Research Chair	December 31, 2012	125 000
TAGALAKIS, Dr. V.	FRSQ	June 30, 2012	34 627
WASSMAN, Dr. S.	Canada Research Chair	June 30, 2013	<u>11 667</u>
TOTAL:			532 501

B. Grants & Bursaries 2010-2011

See attached Excel File

5. NEW HONORS, AWARDS AND APPOINTMENTS

(SEE APPENDIX A)

6. PUBLICATIONS (January – December 2010)

Alaoui-Jamali, Moulay

--Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, **Alaoui-Jamali MA**. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. *J Exp Med*. 207:2421-37, 2010

--**Alaoui-Jamali M**, Toliopoulos P, and Krikor B. Focal adhesion protein trafficking signalling in invasive cancer cells and therapeutic implications. In "Signal Transduction in Cancer Metastasis". Cancer Metastasis Biology & Treatment Series, Springer Life Sciences, 2010

--Alternative and Complementary Therapies for Cancer: Integrative Approaches for Discovery of Conventional Drugs. Editor: **M Alaoui-Jamali**; Springer, NY, 2010

--Lougheed NC and **Alaoui-Jamali MA**. Herbal products-chemotherapy drug interactions from a pharmacological perspective. In "Alternative and Complementary Therapies for Cancer: Integrative Approaches for Discovery of Conventional Drugs". Editor: M Alaoui-Jamali, Springer, NY, 2010

--**Alaoui-Jamali MA** and Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for clinical response to targeted therapy. In: Progress In Cancer Proteomics, Editor: S. Daoud (Washington State University), Humana Press NJ, 2010

Agulnik, Jason

-- Agulnik J, Cohen V, **Miller WH Jr**. EGFR Mutations Detected by Denaturing High-Performance Liquid Chromatography in NSCLC: Impact on Response to Therapy with EGFR-Tyrosine Kinase Inhibitors. *Cancer*, 116(18):4309-17, 2010

--Kasymjanova G, Macdonald N, **Agulnik JS**, Cohen V, Pepe C, Kreisman H, Sharma R, and Small D. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. *Current oncology*, 17:52-58, 2010

Autexier, Chantal

--Fakhoury J, Marie-Egyptienne DT, Londoño-Vallejo JA and **Autexier C**. Telomeric function of mammalian telomerases at short telomeres. *J. Cell Science*, 123:1693-704, 2010

Baron, Murray

-- **M. Baron** M, Bernier P, Côté LF, DeLegge MH, Falovitch G, Friedman G, Gornitsky M, Hoffer LJ, Hudson M, Khanna D, Paterson WG, Schafer D, Toskes PP, Wykes L. Screening and management for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. *Clin Exp Rheumatol* 28 (Suppl 48):S42-

S46, 2010

--Fan X, Pope J, **Baron M**. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). *Rheumatol Int*, 30:1205-10, 2010

--**Baron M**, Hudson M, Steele R, Canadian Scleroderma Research Group. Is serum albumin a marker of malnutrition in chronic disease? The scleroderma paradigm. *J Am Coll Nutr*, 29:144-51, 2010

--Dobkin PL, Liu A, Abrahamowicz M, Ionescu-Ittu R, Bernatsky S, Goldberger A, **Baron M**. Predictors of disability and pain six months after the end of treatment for fibromyalgia. *Clin J Pain*, 26:23-9, 2010

--Newkirk MM, Zbar A, **Baron M**, Manges AR. Distinct bacterial colonization patterns of escherichia coli subtypes associate with rheumatoid factor status in early inflammatory arthritis. *Rheumatology (Oxford)*, 49:1311-6.

--Sekhon S, Pope J, Canadian Scleroderma Research Group, **Baron M**. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. *J Rheumatol*, 37, 2010

--Su H, **Baron M**, Benarroch M, Velly AM, Gravel S, Schipper HM, Gornitsky M, Canadian Scleroderma Research Group. Altered salivary redox homeostasis in patients with Systemic Sclerosis. *J Rheumatol*, 37:1858-63, 2010

--Walker JG, Steele RJ, Schnitzer M, Taillefer S, **Baron M**, Hudson M, Canadian Scleroderma Research Group. The association between disease activity and duration in Systemic Sclerosis. *J Rheumatol*, 37:2299-306, 2010

Batist, Gerald

--Wu JH, Miao W, Hu LG, **Batist G**: Identification and characterization of novel Nrf2-inducers designed to target the intervening region of Keap1. *Chemical Biology & Drug Design* 75:475-480, 2010

--Hu L, Miao W, Loignon M, Kandouz M, **Batist G**: Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. *Cancer Chemotherapy and Pharmacology* 66:467-474, 2010

--Kandouz M, Haidara K, Zhao J, Brisson, ML, **Batist G**: The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. *Cell Cycle* 9:398-407, 2010

--Kandouz M, **Batist G**: Gap junctions and connexins as therapeutic targets in cancer. *Expert Opinion on Therapeutic Targets* 14:681-692, 2010

--Loiselle CG, Edgar L, **Batist G**, Lu J, Lauzier S: The impact of a multimedia informational

intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study. *Patient Education and Counseling* 80:48-55, 2010

--Spatz A, **Batist G**, Eggermont AM: The biology behind the prognostic biomarkers of melanoma. *Current Opinion in Oncology* 22:163-168, 2010

--Salmon A, Lazar V, Spatz A, **Batist G**: Personalized medicine and the hyper-segmentation of cancer patient populations. *Oncology News*: January/February 2010 Issue.

Beitel, Lenore

--Gottlieb B, Beitel LK, Alvarado C, **Trifiro M**: Selection and mutation in the "new" genetics: an emerging hypothesis. *Human Genetics* 127:491-501, 2010

Bergman, Howard

--Wong CH, Weiss D, Sourial N, Karunanathan S, Quail JM, Wolfson C, **Bergman H**. Frailty and its Association with Disability and Comorbidity in a Community-Dwelling Sample of Seniors in Montreal: a cross-sectional study. *Aging Clinical and Experimental Research*, 22:54-62, 2010

--Sourial N, Wolfson C, Zhu B, Fletcher J, Quail J, Karunanathan S, Bandeen-Roche K, Béland F, **Bergman H**. Correspondence analysis is a useful tool to uncover the relationships among categorical variables. *Journal of Clinical Epidemiology*, 63:638-646, 2010

--Rockwood K, **Bergman H**, Hogan DB. A National Strategic Plan for Dementia - A Realistic Goal? *Canadian Journal of Geriatrics*, 13 , 2010

--Destampa M, Vedel I, Mauriat C, Bagaragaza E, Routelous C, **Bergman H**, et al. Diagnostic study, design and implementation of an integrated model of care in France: a bottom-up process with continuous leadership. *Int J Integr Care*, vol 10:e034, 2010

--Massoud F, Lysy P, **Bergman H**. Care of Dementia in Canada: A Collaborative Care Approach with a Central Role for the Primary Care Physician. *Journal of Nutrition Health and Aging*, 14:105-106, 2010

--Sourial N, Wolfson C, **Bergman H**, Zhu B, Karunanathan S, Quail J, Fletcher J, Weiss D, Bandeen-Roche K, Béland F. A correspondence analysis revealed frailty deficits aggregate and are multidimensional. *Journal of Clinical Epidemiology*, 63:647-54, 2010

--Blain H, Carrière I, Sourial N, Bérard C, Favier F, Colvez A, **Bergman H**. Balance and Walking Speed Predict Subsequent 8-Year Mortality Independently of Current and Intermediate Events in Well-Functioning Women Aged 75 Years and Older. *Journal of Nutrition Health and Aging*, 14:595-600, 2010

--Afilalo J, Eisenberg M, **Bergman H**, **Monette J**, Noiseux N, Perrault L, Alexander K, et al. Gait Speed as an Incremental Predictor of Mortality and Major Morbidity in Elderly Patients Undergoing Cardiac Surgery. *Journal of the American College of Cardiology*, 56(20):1668-1676,

2010

--Syddall H, Roberts HC, Evandrou M, Cooper C, **Bergman H**, Aihie Sayer A. Prevalence and correlates of frailty among community-dwelling older men and women: findings from the Hertfordshire Cohort Study. *Age Ageing*, 39:197-203, 2010

Blank, Volker

Chevillard G, Nouhi Z, Derjuga A, Paquet M & **Blank V**. Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene. *FEBS Letters*, 584:923-928, 2010

--Mardini L, Gasiorek J, Derjuga A, Carrière A, Schranzhofer M, Paw BH, Ponka P, **Blank V**. Antagonistic roles of the ERK and p38 MAPK signaling pathways in globin expression, heme biosynthesis and iron uptake. *Biochem J*, 432:145-151, 2010

Blostein, Mark

--Coutu DL, Cuerquis J, El Ayoubi R, Forner KA, Roy R, François M, Griffith M, Lillicrap D, Yousefi AM, Blostein MD, Galipeau J: Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. *Biomaterials*, 32:295-305, 2010

--Peng, H.T, Blostein, M.D, Shek, P.N. Multi-PEGylation of Melittin: Structural Characterization and Hemostatic Effects, *Journal Bioactive and Compatible Polymers*, 25:1:75-97, 2010

--Mahta S, Helmersen D, Provencher S, Hirani N, Rubens FD, De Perrot M, **Blostein M**, Boutet K, Chandy G, Dennie C, Granton J, Hernandez P, Hirsch AM, Laframboise K, Levy RD, Lien D, Martel S, Shoemaker G, Swiston, J, Weinkauff J; for the Canadian Thoracic Society Pulmonary Vascular Disease – STEPH CPG Development Committee; and the Canadian Thoracic Society Canadian Respiratory Guidelines Committee. Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: A clinical practice guideline. *Can Respir J*.17:301-334, 2010

--Charbonneau S, Peng HT, Shek PN, **Blostein MD**: Amphipathic peptides can act as an anticoagulant by competing with phospholipid membranes for blood coagulation factors. *Biochemical and Biophysical Research Communications* 391:1197-1202, 2010

--Crowther MA, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, **Blostein MD**, **Kahn SR**, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C: Oral vitamin K effectively treats international normalized ratio (INR) values in excess of 10. Results of a prospective cohort study. *Journal of Thrombosis and Haemostasis* 104:118-121, 2010

Brewer, Timothy

--Yu OHY, Wong-Keel A, Sheppard D, **Brewer T**. Articular aspergillosis: case report and review. *Int J Infect Dis*, 14:e433-e435, 2010

--Shah L, Choi HW, **Brewer TF**. Challenges in controlling multiple drug-resistant tuberculosis in endemic settings. *University of British Columbia Med J*, 2:11-12, 2010

--Chan E, **Brewer TF**, Madoff LC, Pollack MP, Sonricker AL, Keller M, Freifeld CC, Blench M, Mawudeku A, Brownstein, JS. Global capacity for emerging infectious disease surveillance. *Proceedings of the National Academy of Sciences of the United States of America*. 107:21701-21706, 2010

--Battat R, Seidman G, Chadi N, Chanda MY, Nehme J, Hulme J, Li A, Faridi N, **Brewer TF**. Global health competencies and approaches in medical education: a literature review. *BMC Medical Education*, 10:94, 2010

Cen, Shan

--Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, Fan B, You XF, Wang YP, Liu F, Shao RG, Zhao LX, Yu L, Jiang JD: Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. *The Journal of Biological Chemistry* 285:16546-1, 2010

--Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, You XF, Song DQ, Li ZR, Yu LY, **Cen S**, Hong B, Sun CH, Zhao LX, Kreiswirth B, Perlin D, Shao RG, Jiang JD : Heat-stress cognate 70 as a potential drug target against drug-resistance in host hepatitis B virus. *Antimicrobial Agents and Chemotherapy* 54:2070-2077, 2010

--Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, Li YH, Liu F, You XF, Han YX, Zhao ZY, **Cen S**, Li JR, Song DQ, Jiang JD: Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. *Hepatology (Baltimore, MD.)* 52:845-53, 2010

--Liu ZL, Li XY, Zhang Q, Jia PP, Yang L, Wei XL, Jiang JD, **Cen S**: Establishment and application of a screening anti-HIV-1 drug model targeted unclear trafficking of virus RNA. *Acta Pharmaceutica Sinica*, 45:257-262, 2010

--Zhang Q, Li XY, Jia PP, Liu ZL, Yang L, Wei XL, Zhao LX, Jiang JD, **Cen S**: Establishment and application of a high-throughput screening assay for premature activation of HIV-1 precursors. *Acta Pharmaceutica Sinica* 45:247-252, 2010

Chertkow, Howard

--**Chertkow H**, Whitehead V, Phillips N, Wolfson C, Atherton J, **Bergman H**. Multilingualism (but not always bilingualism) delays the onset of Alzheimer's disease - evidence from a bilingual community. *Alzheimer's Disease & Associated Disorders*, 24:118-25, 2010

--Duchesne S, Bocti C, De Sousa K, Frisoni GB, **Chertkow H**, & Collins DL. Amnestic MCI future clinical status prediction using baseline MRI features. *Neurobiology of Aging*, 31, 1606-17, 2010

--Wittich W, Phillips N, Nasreddine ZS, & **Chertkow H**. Sensitivity and specificity of the

Montreal Cognitive Assessment modified for individuals who are visually impaired. *Journal of Visual Impairment and Blindness*, 104, 360-368, 2010

Cohen, S Robin

--Sévigny A, Dumont S, **Cohen SR**, Frappier A. Helping them live until they die: Volunteer practices in home care. *Non-Profit and Voluntary Sector Quarterly*, 39:734-752, 2010

--Mehta A, **Cohen SR**, Ezer F, Carnevale F, Ducharme F. Family caregivers of palliative cancer patients at home: The puzzle of pain management. *Journal of Palliative Care*, 26:184-93, 2010

--Jones JM, **Cohen SR**, Zimmermann C, Rodin G. Quality of life and symptom burden in patients admitted to an acute Palliative Care Unit. *Journal of Palliative Care*, 26:94-102, 2010

--Shahidi JS, Bernier N, **Cohen SR**. Positive and Negative Contributors to the Quality of Life of Terminally-ill Cancer Patients: Content Analysis of Patients' Answers to the McGill Quality of Life Questionnaire Open-ended Question. *Journal of Palliative Care*, 26:88-93, 2010

--Sévigny A, **Cohen SR**, Dumont S, Frappier A. Making sense of health and illness in palliative care, volunteers' perspectives. *Palliative and Supportive Care*, 8:325-334, 2010

--Mehta A, **Cohen SR**, Carnevale F, Ezer H, Ducharme F. Strategizing a game plan: Family caregivers of palliative cancer patients at home engage in the process of pain management. *Cancer Nursing*, 33:461-469, 2010

--Henry M, **Cohen SR**, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Nuoxin Huang L, Ferland M.-K. & Mayo N. The Meaning-Making intervention (MMi©) increases a sense of meaning in life in women newly diagnosed with advanced ovarian cancer: A randomized control pilot study. *Psycho-Oncology*, 19:1340–1347, 2010

--Heyland DK, Cook DJ, Rocker GM, Dodek PM, Kutsogiannis DJ, Skrobik Y, Jiang X, Day AG, **Cohen SR**. Defining priorities to improve end of life care in Canada. *Canadian Medical Association Journal*, 182:E747-E752, 2010

--Heyland DK, Cook DJ, Rocker GM, Dodek PM, Kutsogiannis DJ, Skrobik Y, Jiang X, Day AG, **Cohen SR**. The Development and Validation of a Novel Questionnaire to Measure Patient and Family Satisfaction with End of Life Care: The Canadian Health Care Evaluation Project (CANHELP) Questionnaire. *Palliative Medicine*, 24:682–695, 2010

Dascal, Andre

--Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, Persing DH. Impact of strain type on detection of toxigenic *Clostridium difficile*: comparison of molecular diagnostic and enzyme immunoassay approaches. *J Clin Microbiol*, 48:3719-24, 2010

Eintracht, Shaun

--**Eintracht S**, Olders R, Hoffer LJ. Metabolic origin of hypovitaminosis C in acutely hospitalized patients. *Evans-Nutrition*. 26:1070-4, 2010

Eisenberg, Mark

--El-Rayes M, Schampaert E, Tardif JC, **Eisenberg MJ**, Afilalo M, NK Kouz S, Lauzon C, Harvey R, Nguyen M, Kouz R, Dery JP, Mansour S, Van Kieu AM, Rinfret S, Huynh T: Safety and effectiveness of enoxaparin following fibrinolytic therapy: results of the acute myocardial infarction (AMI)-QUEBEC registry. *Canadian Journal of Cardiology* 26:431-436, 2010

--Patel A, Tu JV, Waters NM, Ko DT, **Eisenberg MJ**, Huynh T, Rinfret S, Knudtson M, Ghali WA. Access to primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in Canada: A geographic analysis. *Open Med*, 1:13-21, 2010

--Abualsaud AO, **Eisenberg MJ**. Perioperative management of patients with drug-eluting stents. *JACC Cardiovasc Interv*, 3:131-42, 2010

--Mongeon FP, Belisle P, Joseph L, **Eisenberg MJ**, Rinfret S. Adjunctive thrombectomy for acute myocardial infarction: A Bayesian meta-analysis. *Circ Cardiovasc Interv*, 3:6-16, 2010

--**Eisenberg MJ**, Blum LM, Filion KB, Rinfret S, Pilote L, Paradis G, Joseph L, Gervais A, O'Loughlin J. The efficacy of smoking cessation therapies in cardiac patients: A meta-analysis of randomized controlled trials. *Can J Cardiol*, 26:73-9, 2010

--Lawler PR, Filion KB, **Eisenberg MJ**. Correcting anemia in heart failure: The efficacy and safety of erythropoiesis-stimulating agents. *J Card Fail*, 16:649-58, 2010

--Chaudhry R, Chaudhry F, Huynh T, Lader E, Rashid S, Okrainec K, Wou K, **Eisenberg MJ**. Effect of smoking on age at the time of coronary artery bypass graft surgery; Baseline data results -from the ROSETTA-CABG registry. *Heart Asia*, 2:48-51, 2010

--Pagé M, Doucet M, **Eisenberg MJ**, Behloul H, Pilote L. Temporal trends in revascularization and outcomes after acute myocardial infarction in the very elderly. *CMAJ*, 182:1415-20, 2010

--Afilalo J, **Eisenberg MJ**, Morin JF, Bergman H, Monette J, Noiseux N, Perrault LP, Alexander KP, Langlois Y, Dendukuri N, Chamoun P, Kasparian G, Robichaud S, Gharacholou SM, Boivin JF. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. *J Am Coll Cardiol*, 56:1668-76, 2010

--Eisenberg MJ: *The Physician-Scientist's Career Guide*. Springer-Humana Press, 2010

Ernst, Pierre

--Lavoie KL, Bouthillier D, Bacon SL, Lemiere C, Martin J, Hamid Q, Ludwig M, Olivenstein R, **Ernst P**. Psychological distress and maladaptive coping styles in patients with severe vs moderate asthma. *Chest*, 137:1324-31, 2010

--Ramos-Barbón D, Fraga-Iriso R, Brienza NS, Montero-Martínez C, Vereza-Hernando H,

Olivenstein R, Lemiere C, **Ernst P**, Hamid QA, Martin JG. T Cells localize with proliferating smooth muscle alpha-actin+ cell compartments in asthma. *Am J Respir Crit Care Med*, 182:317-24, 2010

--Chan-Yeung M, Anthonisen NR, Becklake MR, Bowie D, Buist SA, Dimich-Ward H, **Ernst P**, Sears MR, Siersted HC, Sweet L, Van Til L, Manfreda J. Geographical variations in the prevalence of atopic sensitization in six study across Canada. *Allergy*, 51:1404-1413, 2010

Ferrario, Cristiano

--**Ferrario C, Basik M**: Physiopathology of colorectal metastasis. In: *Cancer Metastasis Biology & Treatment series*. Huot J, Beauchemin N, eds. Springer Publishers, 2010

-- Hamel S, Bouchard A, **Ferrario C**, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, **Miller WH Jr.**, Basik M. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. *Breast Cancer Res Treat*. 120(1):47-57, 2010

Foulkes, William

--Rio Frio T, Haanpää M, Pouchet C, Pylkäs K, Vuorela M, Tischkowitz M, Winqvist R, **Foulkes WD**. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families. *J Hum Genet*, 55:842-3, 2010

--Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I, Cancer Family Registry B, Confab K, Baglietto L, Giles GG, Goldgar D, **Foulkes WD**, Hopper JL. A PALB2 mutation associated with high risk of breast cancer. *Breast Cancer Res*, 12(6):R109, 2010

--Metcalf K, Lubinski J, Lynch HT, Ghadirian P, **Foulkes WD**, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; for the Hereditary Breast Cancer Clinical Study Group. Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. *J Natl Cancer Inst*, 102(24):1874-8, 2010

--**Foulkes WD**, Traffic Control for BRCA1. *N Engl J Med*. 362:755-6, 2010

--Greenwood CM, Sun S, Veenstra J, Hamel N, Niell B, Gruber S, **Foulkes WD**. How old is this mutation? - A study of three Ashkenazi Jewish founder mutations. *BMC Genet*, 11:39, 2010

--Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, **Foulkes WD**, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Thibodeau SN, McDonnell SK, Hebbing S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Farnham JM, Cannon-Albright LA, Camp NJ; International Consortium for Prostate Cancer Genetics. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and

sumLOD analyses. *Prostate*, 70:735-44, 2010

--Lachapelle J, Gilbert L, Artho G, Alcindor T, Amre R, Arseneau J, **Foulkes WD**. Colonic or coelomic? *Lancet*, 375(9728):1844, 2010

--Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, **Foulkes WD**, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med*, 7(5):e1000279, 2010

--**Foulkes WD**, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer- a reappraisal. *Nat Rev Clin Oncol*. 7:348-53, 2010

--Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, **Foulkes WD**, Huntsman DG. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. *Breast Cancer Res Treat*, 121:347-54, 2010

--**Foulkes WD**, Tomlinson IP. Are we there yet?: journeying along the cancer genetic information superhighway. *Curr Opin Genet Dev*, 20:197-200, 2010

--Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. *Gynecol Oncol*, 118:155-9, 2010

--Akbari MR, Tonin P, **Foulkes WD**, Ghadirian P, Tischkowitz M, Narod SA. RAD51C germline mutations in breast and ovarian cancer patients. *Breast Cancer Res*, 12:404, 2010

--Yilmaz A, Hamel N, Schwartz CE, Houlston RS, Harper JL, **Foulkes WD**. A genome-wide analysis of loss of heterozygosity and chromosomal copy number variation in Proteus syndrome using high-density SNP microarrays. *J Hum Genet*. 55:627-30, 2010

--Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, **Foulkes WD**. Is breast cancer the same disease in Asian and Western countries? *World J Surg*. 34:2308-24, 2010

--Shuen A, **Foulkes WD**. Clinical implications of next-generation sequencing for cancer medicine. *Curr Oncol*. 17:39-42, 2010

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 363(20):1938-48, 2010

--Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, **Foulkes WD**, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun

P, Krewski D, Narod S; the Hereditary Breast Cancer Clinical Study Group. Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. *Breast*, 19:479-83, 2010

--Ginsburg OM, Kim-Sing C, **Foulkes WD**, Ghadirian P, Lynch HT, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. BRCA1 and BRCA2 families and the risk of skin cancer. *Fam Cancer*. *Fam Cancer*. 9:489-93, 2010

--Bahubeshi A, Bal N, Rio Frio T, Hamel N, Pouchet C, Yilmaz A, Bouron-Dal Soglio D, Williams GM, Tischkowitz M, Priest JR, **Foulkes WD**. Germline DICER1 mutations and familial cystic nephroma. *J Med Genet*. 47:863-6, 2010

--Levesque S, Ahmed N, Nguyen VH, Nahal A, Blumenkrantz M, Puligandla P, Chong G, **Foulkes WD**. Pediatrics. Neonatal Gardner Fibroma: A Sentinel Presentation of Severe Familial Adenomatous Polyposis. *Pediatrics*. 126:e1599-602, 2010

--Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, Wark L, Capelli C, Reis-Filho JS, Mai S, Pastinen T, Tischkowitz MD, Marcus VA, **Foulkes WD**. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. *N Engl J Med*, 363(27):2628-37, 2010

--Hollmann CA, Tzankov A, Martínez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, **Foulkes W**, Nadeau J, Dirnhofer S, **Aloyz R**: Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. *Leukemia Research*, 34:585-593, 2010

Galipeau, Jacques

--Taljaard M, Ward MR, Kutryk MJ, Courtman DW, Camack NJ, Goodman SG, Parker TG, Dick AJ, **Galipeau J**, Stewart DJ: Rationale and design of enhanced angiogenic cell therapy in acute myocardial infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. *American Heart Journal*, 159:354-360, 2010

-Romieu-Mourez R, François M, Abate A, Boivin MN, Birman E, Bailey D, Bramson JL, Forner K, Young YK, Medin JA, **Galipeau J**: Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN- γ and tumor necrosis factor- α priming. *Cancer Research*, 70:7742-7747, 2010

--Rafei M, **Galipeau J**: A chimeric cytokine to help autoimmune diseases. *Médecine Sciences: M/S* 26:137-139, 2010

--Darlington PJ, Boivin MN, Renoux C, François M, **Galipeau J**, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A: Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. *Annals of Neurology*, 68:540-545, 2010

--Williams P, Rafei M, Bouchentouf M, Raven J, Yuan S, Cuerquis J, Forner KA, Birman E, **Galipeau J**: A fusion of GM-CSF and IL-21 initiates hypersignaling through the IL-21R α chain with immune activating and tumoricidal effects in vivo. *Molecular Therapy*, 18:1293-1301, 2010

Gatignol, Anne

--Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, **Gatignol A**, Akazawa D, Wakita T, Meurs EF: Hepatitis C virus controls interferon production through PKR activation. PLoS One 5:e10575, 2010

Greenaway, Christina

--Fischer M, Nicole L, Staples E, Hills S and the Japanese encephalitis virus vaccines workgroup (including **C Greenaway**). Japanese encephalitis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 59 (No. RR-1), 2010

--Pottie K, **Greenaway C**, Feightner J, Welch V, Kirmayer L, Swinkels H, Rashid M, Narasiah L, MacDonald N, Tugwell P, on behalf of the Canadian Collaboration for Immigrant and Refugee Health (CCIRH). Clinical Preventive Recommendations from Evidence Reviews for Primary Care for Newly Arrived Immigrants and Refugees to Canada (Summary) Can. Med Assoc. J, 10.1503/CMAJ.090313, 2010

--**Greenaway C**, Sandoe A, Kitai I, Vissandjee B, Gruner D, Menzies D, Schwartzman K. Tuberculosis: Evidence Review for Newly Arriving Immigrants and Refugees. Can. Med. Assoc. J, 10.1503/CMAJ.090302, 2010

--JE, Gershman M, Fischer M and the Yellow Fever Vaccine Work Group (including **C Greenaway**). Yellow Fever Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 59 (No. RR-7), 2010

--Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, **Greenaway C**, Lian Lim P, Schwartz E, Wilder-Smith A, Wilson ME. Vaccine Preventable Diseases in Returned International Travelers: Results from the GeoSentinel Surveillance Network. Vaccine, 28(46):7389-95, 2010 Epub 2010 Sep 17.

Hiscott, John

--Diallo JS, Boeuf FL, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, Mactavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, **Hiscott J**, Atkins H, Lichty BD, Bell JC. A High-throughput pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Mol Ther. 18: 1123-1129, 2010

--Luig C, Köther K, Gaeste M, **Hiscott J**, Wixler V and Ludwig S. MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. FASEB J. 24: 4068-4077, 2010

--Olière S, Hernandez E, Lézin A, Nguyen TL, Arguello M, Wilkinson P, Sekaly R, Césaire R and **Hiscott J**. HTLV-1 evades antiviral immunity via upregulation of SOCS1 PLoS Pathogens, 6: e1001177, 2010

--Samuel S, Tumilasci V, Oliere S, Nguyễn T L-A, Shamy A, Bell J and **Hiscott J**. VSV oncolysis in combination with the BCL-2 inhibitor GX15-070 overcomes apoptotic resistance in CLL cells Mol. Therapy, 18: 2094-2103, 2010

--Paz S, Douville R, **Hiscott J**. Curtailing IRF signaling with the E3 ligase RAUL. *Immunity* 33: 833-835, 2010

--Douville RN, **Hiscott J**: The interface between the innate interferon response and expression of host retroviral restriction factors. *Cytokine* 52:108-115, 2010

-- Lin R, Paz S and **Hiscott J**. Tom70 imports antiviral immunity to the mitochondria. *Cell Res* . 20:971-3 , 2010

--Nguyen TL, Wilson MG, **Hiscott J**: Oncolytic viruses and histone deacetylase inhibitors—a multi-pronged strategy to target tumor cells. *Cytokine and Growth Factor Reviews* 21:153-159, 2010

Hoffer, L. John

--**Hoffer LJ**. Orthomolecular psychiatry: past, present and future. *J. Orthomolecular Med*, 25:56-66, 2010

--**Hoffer LJ**. Vitamin C deficiency in a population of young Canadian adults. *Am J Epidemiol*, 171:387-388, 2010

-- Rebecca Evans-Olders R, **Eintracht S**, Hoffer LJ. Metabolic origin of hypovitaminosis C in acutely hospitalized patients. *Nutrition*, 26:1070-4, 2010

-- **Hoffer LJ**. Micronutrients and mental disorders. *The Whitehall-Robins Report*, 19:1-2, 2010

Hudson, Marie

--Bassel M, **Hudson M**, Taillefer SS, Schieir O, **Baron M**, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: Results from a Canadian national survey. *Rheumatology (Oxford)* 2010

--Hudson M, Baron M, Lo E, Weinfeld J, Furst DE, Khanna D. An international, web-based, prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results. *Int J Rheumatol*, 347402, 2010

--El-Baalbaki G, Razykov I, **Hudson M**, Bassel M, **Baron M**, Thombs BD. Association of pruritus with quality of life and disability in systemic sclerosis. *Arthritis Care Res (Hoboken)*, 62:1489-95, 2010

--**Hudson M**, Masetto A, Steele R, Arthurs E, **Baron M**, Canadian Scleroderma Research Group. Reliability of widefield capillary microscopy to measure nailfold capillary density in systemic sclerosis. *Clin Exp Rheumatol*, 28(5 Suppl 62):S36-41, 2010

--**Hudson M**, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. *Arthritis Care Res (Hoboken)*, 62:805-10, 2010

--**Hudson M**, Impens A, **Baron M**, Seibold J, Thombs B, Walker J, Canadian Scleroderma Research Group, Steele R. Discordance between patient and physician assessments of disease severity in Systemic Sclerosis. *J Rheumatol*, 37:2307-12, 2010

--**Hudson M**, Fritzler MJ, **Baron M**, Canadian Scleroderma Research Group. Systemic sclerosis: Establishing diagnostic criteria. *Medicine (Baltimore)*, 89:159-65, 2010

--Jewett LR, **Hudson M**, Haythornthwaite JA, Heinberg L, Wigley FM, **Baron M**, Thombs BD. Development and validation of the brief-satisfaction with appearance scale for systemic sclerosis. *Arthritis Care Res (Hoboken)*, 62:1779-86, 2010

--Milette K, Razykov I, Pope J, **Hudson M**, Motivala SJ, **Baron M**, Thombs BD. Clinical correlates of sleep problems in systemic sclerosis: The prominent role of pain. *Rheumatology (Oxford)*, 2010

--Milette K, **Hudson M**, **Baron M**, Thombs BD. Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: Internal consistency reliability, convergent validity and clinical correlates. *Rheumatology (Oxford)*, 49:789-96, 2010

--Mittoo S, Gelber AC, Hitchon CA, Silverman ED, Pope JE, Fortin PR, Pineau C, Smith CD, Arbilla H, Gladman DD, Urowitz MB, Zummer M, Clarke AE, Bernatsky S, **Hudson M**, Tucker LB, Petty RE, Peschken CA. Clinical and serologic factors associated with lupus pleuritis. *J Rheumatol*, 37:747-53, 2010

Joyal, Dominique

--**Joyal D**, Filion KB, **Eisenberg MJ**. Effectiveness and safety of drug-eluting stents in vein grafts: A meta-analysis. *Am Heart J*, 159:159-69, 2010

--**Joyal D**, Afilalo J, Rinfret S. Effectiveness of percutaneous recanalization of chronic total occlusions: a systematic review and meta-analysis. *Am Heart J*, 160:179-87, 2010

Kahn, Susan

--**Kahn S R**, Shrier I, Shapiro S, Houweling A H, Hirsch A M, Reid R D, Kearon C, Rabhi K, Rodger M A, Kovacs M J, Anderson D R, and Wells P S. Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. *CMAJ*. 2010

--Emed JD, Morrison DR, Des Rosiers L, **Kahn SR**: Definition of immobility in studies of thromboprophylaxis in hospitalized medical patients: a systematic review. *Journal of Vascular Nursing* 28:54-66, 2010

--Luong ML, Libman M, Dahhou M, Chen MF, **Kahn SR**, Goulet L, Séguin L, Lydon J, McNamara H, Platt RW, Kramer MS: Vaginal douching, bacterial vaginosis, and spontaneous preterm birth. *Journal of Obstetrics and Gynaecology Canada* 32:313–320, 2010

--Spector JT, **Kahn SR**, Jones MR, Jayakumar M, Dalal D, Nazarian S: Migraine headache and

ischemic stroke risk: an updated meta-analysis. American Journal of Medicine 123:612-624, 2010

--Vazquez SR, **Kahn SR**: Postthrombotic syndrome. Cardiology Patient Page. Circulation 121:e217-219, 2010

--Crowther MA, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, **Blostein MD, Kahn SR**, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C: Oral vitamin K effectively treats international normalized ratio (INR) values in excess of 10. Results of a prospective cohort study. Journal of Thrombosis and Haemostasis 104:118-121, 2010

--**Kahn SR**, Morrison DR, Emed J, **Tagalakis V, Shrier I**: Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008201. DOI: 10.1002/14651858.CD008201.

--Kramer MS, **Kahn SR**, Platt RW, Genest J, Chen MF, Goulet L, Séguin L, Lydon J, McNamara H, Libman M, Dahhou M, Lamoureux J, Skogstrand K, Thorsen P: Mid-trimester maternal plasma cytokines and CRP as predictors of spontaneous preterm birth. Cytokine 49:10-14, 2010

Karaplis, Andrew

--Zhang HW, Ding J, Jin JL, Guo J, Liu JN, **Karaplis A**, Goltzman D, Miao D: Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice. Journal of Bone and Mineral Research, 25:640-652, 2010

--Simmonds CS, Karsenty G, **Karaplis AC**, Kovacs CS: Parathyroid hormone regulates fetal-placental mineral homeostasis. Journal of Bone and Mineral Research, 25:594-605, 2010

--Sun W, Sun W, Liu J, Zhou X, Xiao Y, Karaplis A, *Pollak MR, Brown E, Goltzman D, Miao D: Alterations in phosphorus, calcium and PTHRP contribute to defects in dental and dental alveolar bone formation in calcium-sensing receptor-deficient mice. Development, 137:985-992, 2010

Kleiman, Lawrence

--Pavon-Eternod M, Wei M, Pan T and **Kleiman, L**. Profiling non-lysyl tRNAs in HIV-1. RNA, 16:267-273, 2010

--**Kleiman L**, Jones C, and Musier-Forsyth K. Formation of the tRNA^{Lys} Packaging Complex in HIV-1 FEBS Lett. 584:359-365, 2010

Langleben, David

--Star GP, Giovinazzo M, **Langleben D**. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells. A potential mechanism for

elevated ET-1 levels in pulmonary arterial hypertension. *Microvasc Res*, 80:349-354, 2010

--Corris P, **Langleben D**: The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. *The European Respiratory Journal*, 35:460-461, 2010

Laporta, Donald (Denny)

--Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, **Laporta D**, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. *Crit Care Med*, 38:1773-85, 2010

--Gagnon J, **Laporta D**, Béique F, Langlois Y, Morin JF. Clinical relevance of ventilation during cardiopulmonary bypass in the prevention of postoperative lung dysfunction. *Perfusion*, 25:205-10, 2010

Laughrea, Michael

--Abrahamyan LJ, Chatel-Chaix L, Ajamian L, Milev MP, Monette A, Clément, JF, Song R, Lehmann, M, DesGroseillers L, **Laughrea M**, Mouland AJ: Novel Staufen1 ribonucleoproteins prevent formation of stress granules but favour encapsidation of HIV-1 genomic RNA. *Journal of Cell Science*, 123:369-383, 2010

--Jalalirad M and **Laughrea M**: Formation of immature and mature genomic RNA dimers in wild-type and protease-inactive HIV-1: differential roles of the Gag polyprotein, nucleocapsid proteins NCp15, NCp9, NCp7, and the dimerization initiation site. *Virology*, 407:225-236, 2010

Leblanc, Andrea

--Noorbakhsh F, Ramachandran R, Barsby N, Ellestad K, **LeBlanc AC**, Dickie P, Baker G, Hollenberg MD, Cohen E & Power C. HIV-1 viral protein R causes caspase-6 proteolysis and interferon-alpha induction leading to astrocyte apoptosis. *FASEB J*, 24:1799-812, 2010

--Halawani D, Tessier S, Anzellotti D, Bennett DA, Latterich M & **LeBlanc AC**. Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer disease: a novel link to dysfunction in ubiquitin proteasome system mediated protein degradation. *J. Neurosci*, 30(17):6132-42, 2010

--Lee AW, Champagne N, Wang X, Su XD, Goodyer CG, **LeBlanc AC**. Alternatively spliced caspase-6b isoform inhibits the activation of caspase-6a. *J Biol Chem*, 285(42):31974-84, 2010

--Wang XJ, Cao Q, Liu X, Wang KT, Mi W, Zhang Y, Li LF, **LeBlanc AC**, Su XD: Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. *EMBO Reports*, 11:841-847, 2010

Lehoux, Stephanie

--Ait-Oufella H, Maury E, **Lehoux S**, Guidet B, Offenstadt G: The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. *Intensive Care Medicine* 36:1286-1298, 2010

--Lemarié CA, Tharaux PL, **Lehoux S**: Extracellular matrix alterations in hypertensive vascular remodeling. *Journal of Molecular and Cellular Cardiology* 48:433-439, 2010

Lin, Rontuang

-- Lin R, Paz S and Hiscott J. Tom70 imports antiviral immunity to the mitochondria. *Cell Res* . 20:971-3 , 2010

--Nakhaei P, Hiscott J and **Lin R** . Sting-ing The Antiviral Pathway. *J Mol Cell Biol* . 2:110-2, 2010

Liang, Chen

--Zhang J and **Liang C**. BST-2 inhibits HIV-1 infectivity. *Journal of Virology*. 84:12336-12343, 2010

--Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, **Liang C**, Winberg MA. Tetherin restricts direct cell-to-cell infection of HIV-1. *Retrovirology*. 7:115, 2010

MacNamara, Elizabeth

--**MacNamara E**, Halliday D, Lau S, Vaknin Z, Deland C, Levental M, Gotlieb R, Kaufer R, How J, Cohen E, Gotlieb WH. Robotic radical hysterectomy: comparison of outcomes and cost. *Journal of Robotic Surgery*, ISSN (1863-2483), 4:4, 2010

Miller, Mark

--Mulvey MR, Boyd DA et al (including **Miller MA**). Hypervirulent *Clostridium difficile* strains in hospitalized patients, Canada. *Emerg Inf Dis* 16:678-81, 2010

--**Miller M**, Gravel D and Mulvey M. Surveillance data on outbreaks of *Clostridium difficile* infection in Ontario, Canada, in 2008-09 [reply] *Clin Infec Dis*, 50:1686-1687, 2010

--**Miller M**, Bernard L, Thompson M, et al. Lack of increased colonization with Vancomycin-Resistant Enterococci during preferential use of Vancomycin for treatment during an outbreak of healthcare-associated *Clostridium difficile* infection. *Infection Control & Hospital Epidemiology*. 31:710-715, 2010

--**Miller M**. Fidaxomicin (OPT-80) for the treatment of *Clostridium difficile* infection. *Expert Opin. Pharmacother*. 11:1569-78, 2010

--**Miller M**, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, and the Canadian Nosocomial Infection Surveillance Program

(CNISP). Hospital-acquired Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clinical Infectious Diseases 50:194-201, 2010

Miller, Wilson H Jr

-- Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, **Miller WH Jr**, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 116(5):1272-80, 2010

-- . Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, **Miller WH Jr**, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology, 78(5-6):340-7, 2010

-- McNamara S*, Nichols J*, Wang H, **Miller WH Jr**, *co-first authors. Targeting PKCdelta-mediated topoisomerase IIbeta overexpression subverts the differentiation block in a retinoic-acid resistant cell line. Leukemia, 24 (4):729-39, 2010

Monette, Johanne

--Puts M, Girre V, **Monette J**, Wolfson C, Monette M, Batist G, **Bergman H**. Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: a qualitative study. Critical Reviews in Oncology/Hematology, 74:87-96, 2010

--Puts M, **Monette J**, Girre V, Wolfson C, Monette M, Batist G, **Bergman H**. Characteristics of older newly-diagnosed cancer patients refusing cancer treatments. Supportive Care in Cancer, 18:969-974, 2010

--Puts M, **Monette J**, Girre V, Costa-Lima B, Wolfson C, Batist G, **Bergman H**. Potential medication problems in older newly-diagnosed cancer patients in Canada during cancer treatment? Results of a prospective pilot cohort study. Drugs & Aging, Vol 27:559-572, 2010

--Puts MTE, **Monette J**, Girre V, Monette M, Batist G, Wolfson C, **Bergman H**. Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot study. Critical Reviews in Oncology/Hematology, 76:142-151, 2010

Morais, José

--Pereira SRM, Chiu W, Turner A, Chevalier S, Joseph, L, Huang AR and **Morais JA**. How can we improve targeting of frail elderly patients to a geriatric day-hospital rehabilitation program. BMC Geriatrics, 10:82, 2010

--Goulet E, Khursigara, Z, Gougeon R and **Morais JA**. Postprandial insulin sensitivity and

thermogenesis responses in frail elderly women. *Appl Physiol Nut Metab*, 35:526-33, 2010
--Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL and **Morais JA**. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. *J Cachexia Sarcopenia Muscle*, 1:177-185, 2010

Mouland, Andrew

--Milev MP, Brown CM, **Mouland AJ**: Live cell visualization of the interactions between HIV-1 Gag and the cellular RNA-binding protein Staufen1. *Retrovirology*, 7:41, 2010

Nessim, Sharon

--Nessim SJ, Bargman JM and Jassal SV. Relationship between double-cuff versus single-cuff peritoneal dialysis catheters and risk of peritonitis. *Nephrol Dial Transplant*, 25:2310-4, 2010

--Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: Is what's good for the kidney also good for the peritoneum? *Kidney Int*, 78:23-8, 2010

--Nessim SJ, Lipman ML. Make your diagnosis: Cyanosis in a hemodialysis patient. *Kidney Int*, 78:327-8, 2010

Panasci, Lawrence

--Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, **Panasci L**, Ianuli C, Kahan Z, Fukase K, Lindemann JPO, Macpherson MP, Neven P. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer. *Breast Cancer Research and Treatment*, 123 453-461, 2010

--Algire C, Amrein L, Zakikhani M, **Panasci LC**, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. *Endocrine-Related Cancer*, 17 351-360, 2010

Pantopoulos, Kostas

--Sebastiani G and **Pantopoulos K**: Iron metabolism and disease. In: Cellular and Molecular Biology of Metals. Zalups RK, Koropatnick J, eds. Taylor & Francis, pp 351-378, 2010

--Schümann K, Herbach N, Kerling C, Seifert M, Fillebeen C, Prysich I, Reich J, Weiss G and **Pantopoulos K**. Iron absorption and distribution in $TNF^{\Delta ARE/+}$ mice a model of chronic inflammation. *J. Trace Elem. Med. Biol.*, 24:58-66, 2010

--Maffettone C, Chen G, Drozdov I, Ouzounis C and **Pantopoulos K**. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert PLoS ONE 5 pp. e10163, 2010

--Papadakis AI, Paraskeva E, Peidis P, Muaddi H, Raptis L, **Pantopoulos K**, Simos G and Koromilas A. The eIF2 α kinase PKR is implicated in the hypoxic response by acting as a transcriptional suppressor of HIF1A gene *Cancer Res.* 70:7820-7829, 2010

--Fillebeen C and **Pantopoulos K**. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells J. Hepatol. 53:995-999, (editorial in pp. 990-992), 2010

--Hausmann A and **Pantopoulos K**. Iron regulatory proteins Biochemical Aspects of Human Nutrition (eds. Avigliano L. and Rossi L.) Research Signpost, 101-126, 2010

Pepe, Carmela

--Puts M T, Monette J, Girre V, **Pepe C**, Monette M, Assouline S, Panasci L, Basik M, Miller W H, Jr, Batist G, Wolfson C, and Bergman H. Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Critical reviews in oncology/hematology. 2010

Pollak, Michael

--Algire C, Amrein L, Zakikhani M, Panasci L, **Pollak M**. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase, 17:351-60, 2010

--Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, **Pollak M**. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose, 298: 246-53, 2010

--Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, **Pollak M**, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer Cohort Consortium, 19:3873-84, 2010

--Douglas JB, Silverman DT, **Pollak MN**, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial, 19:2298-306, 2010

--Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, **Pollak M**. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer, 70:848-55, 2010

--Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, **Pollak M**, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression, 107:14134-9, 2010

--Gill JK, Wilkens LR, **Pollak MN**, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort, 70:906-15, 2010

- Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, **Pollak M**, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report, 60:207-21, 2010
- Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, **Pollak M**, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report, 33:1674-85, 2010
- Grimaldi-Bensouda L, Marty M, **Pollak M**, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin and cancer, 376:769-70, 2010
- Hou M, Venier N, Sugar L, Musquera M, **Pollak M**, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet, 397:537-42, 2010
- Inoue T, Zakikhani M, David S, Algire C, Blouin MJ, **Pollak M**. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man, 70:1628-35, 2010
- Johnson JA, **Pollak M**. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes, 53:2086-8, 2010
- Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, **Pollak M**, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis, 122:647-59, 2010
- Major JM, **Pollak MN**, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and risk of kidney cancer in men, 103:132-5, 2010
- Major JM, Stolzenberg-Solomon RZ, **Pollak MN**, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and liver cancer risk in male smokers, 103:1089-92, 2010
- Mireuta M, Darnel A, **Pollak M**. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription, 28:243-55, 2010
- Mucci LA, Stark JR, **Pollak MN**, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk:a prospective study, 19:484-91, 2010
- Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, **Pollak M**. Finasteride modifies the relation between serum c-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial, 3:279-89, 2010
- Okereke OI, Kurth T, **Pollak MN**, Gaziano JM, Grodstein F. Fasting plasma insulin, c-peptide and cognitive change in older men without diabetes: results from the Physicians' Health Study II, 34:200-7, 2010
- Pollak M**. Beyond steroid hormones: the new cancer endocrinology, 11:501-2, 2010
- Pollak M**. Metformin and other biguanides in oncology: advancing the research agenda,

3:1060-5, 2010

--**Pollak M**, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre?, 64:628-36, 2010

--Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H, **Pollak MN**, Aparicio SA, Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas, 70:8770-81, 2010

--Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, **Pollak MN**, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians, 19:3089-101, 2010

--Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, **Pollak M**, Freedland SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model, 13:350-5, 2010

--Tsilidis KK, Brancati FL, **Pollak MN**, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort, 21:1-10, 2010

--Zakikhani M, Blouin MJ, Piura E, **Pollak MN**. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells, 123:271-9, 2010

Ponka, Prem

--Horvathova M, **Ponka P**, Divoky V. Molecular basis of hereditary iron homeostasis defects. Hematology, 15:96-111, 2010

--Mikhael MR, Sheftel AD, **Ponka P**. Ferritin does not donate its iron for haem synthesis in macrophages. Biochem J, 429:463-471, 2010

--**Ponka P**, Prchal JT. Hereditary and Acquired Sideroblastic Anemias. In: Williams Hematology, 8th edition (Lichtman MA, Beutler T, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds.) McGraw-Hill, pp 865-872, 2010

--Richardson DR, Huang ML-H, Whitnall M, Becker EM, **Ponka P**, and Suryo Rahmanto Y. The in's and out's of mitochondrial iron-loading: The metabolic defect in Friedreich's ataxia. J Mol Med, 88:323-329, 2010

--Richardson D, Lane D, Becker E, Michael Huang M, Whitnall M, Suryo Rahmanto Y, Sheftel A, **Ponka P**. Mitochondrial iron trafficking and the integration of iron metabolism between the

mitochondrion and cytosol. *Proc Natl Acad Sci USA*, 107:10775-10782, 2010

--Soe-Lin S, Apte SS, Mikhael MR, Kayembe LK, Nie G, **Ponka P**. Both Nramp1 and DMT1 are necessary for efficient macrophage iron recycling. *Exp Hematol*, 38:609-617, 2010

--Zhang Y, Mikhael M, Xu D, Li Y, Soe-Lin S, Ning B, Li W, Nie G, Zhao Y, **Ponka P**. Cytosolic ferritin degradation is prerequisite for mitochondrial ferritin-induced iron mobilization. *Antioxid Redox Signal*, 13:999-1009, 2010

Richard, Stephane

--Sellier C, Rau F, Y Liu, F Tassone, RK Hukema, R Gattoni, A Schneider, **S Richard**, R Willemsen, D J Elliott, PJ Hagerman, and N Charlet-B. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. *EMBO J*, 29:1248-61, 2010

--Doukhanine E, Gavino C, JD Haines G Almazan and **S Richard**. The QKI-6 RNA binding protein regulates actin-interacting protein-1 mRNA stability during oligodendrocyte differentiation, *Mol Biol Cell*, 21:3029-40, 2010

--Wang Y, Lacroix G, J Haines, E Doukhanine, G Almazan, and **S Richard**. The QKI-6 RNA binding protein localizes with the MBP mRNAs in stress granules of glial cells. *PLoS One*, e12824, 2010

--Binda O, LeRoy G, DJBua, BA Garcia, O Gozani, and **S Richard** (2010). Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: Regulation of lysine methyltransferases by physical interaction with their substrates. *Epigenetics*, 5:768-776. 2010

--**Richard S**. Reaching for the STARS: Linking RNA binding proteins to diseases. [STAR Proteins](#), Editors K. Artzt and T. Volk, Landes Bioscience and Springer, Business Media, 2010

Richards, J. Brent

--LS Greene-Finestone, C Berger, M de Groh, DA Hanley, N Hidioglou, K Sarafin, S Poliquin, J Krieger, JB Richards, D Goltzman; CaMos Research Group. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. *Osteoporosis International*, DOI: 10.1007/s00198-010-1362-7, Epub Aug 21, 2010

--Ladouceur M, Leslie WD, Dastani Z, Goltzman D, **Richards JB**. An Efficient Paradigm for Genetic Epidemiology Cohort Creation. *PLoS One*, 5:e14045, 2010

--Panicker V, SG Wilson, JP Walsh, **JB Richards**, SJ Brown, JP Beilby, AP Bremner, GL Surdulescu, E Qweitin, I Gillham-Naseny, N Soranzo, EM Lim, SJ Fletcher, TD Spector. A locus on chromosome 1p36 is associated with thyrotropin and thyroid function as identified by genome-wide association study. *American Journal of Human Genetics*, 87:430-5, 2010

--Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M,

Rice K, Goltzman D, Hidirolou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD: Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet*, 376:180-188, 2010

--Heid IM, Henneman P, Hicks A, Coassin S, Winkler T, Aulchenko YS, Fuchsberger C, Song K, Hivert MF, Waterworth DM, Timpson NJ, **Richards JB**, Perry JR, Tanaka T, Amin N, Kollerits B, Pichler I, Oostra BA, Thorand B, Frants RR, Illig T, Dupuis J, Glaser B, Spector T, Guralnik J, Egan JM, Florez JC, Evans DM, Soranzo N, Bandinelli S, Carlson OD, Frayling TM, Burling K, Smith GD, Mooser V, Ferrucci , Meigs JB, Vollenweider P, Dijk KW, Pramstaller P, Kronenberg F, van Duijn CM: Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. *Atherosclerosis*, 208:412-420, 2010

--Hsu YH, Zillikens MC, Wilson SG, Farber CR, Demissie S, Soranzo N, Bianchi EN, Grundberg E, Liang L, **Richards JB**, Estrada K, Zhou Y, van Nas A, Moffatt MF, Zhai G, Hofman A, van Meurs JB, Pols HA, Price RI, Nilsson O, Pastinen T, Cupples LA, Lusi AJ, Schadt EE, Ferrari S, Uitterlinden AG, Rivadeneira F, Spector TD, Karasik D, Kiel DP: An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. *PLoS Genetics* 6, e1000977, 2010

--Kung AW, Xiao SM, Cherny S, Li GH, Gao Y, Tso G, Lau KS, Luk KD, Liu JM, Cui B, Zhang MJ, Zhang ZL, He JW, Yue H, Xia WB, Luo LM, He SL, Kiel DP, Karasik D, Hsu YH, Cupples LA, Demissie S, Stykarsdottir U, Halldorsson BV, Sigurdsson G, Thorsteinsdottir U, Stefansson K, Richards JB, Zhai G, Soranzo N, Valdes A, Spector TD, Sham PC: Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. *American Journal of Human Genetics*, 86:229-239, 2010

Rosenblatt, David

--Quadros EV, Lai S, Nakayama Y, Sequeira M, Hannibal L, Wang S, Jacobsen DW, Fedesov S, Wright E, Gallagher RC, Anastasio N, Watkins D, **Rosenblatt DS**. Positive Newborn Screen for Methylmalonic Aciduria identifies the First Mutation in TCblR/CD320, the Gene for Cellular Uptake of Transcobalamin-Bound Vitamin B12. *Hum Mutat*, 31:924-929, 2010

--Anastasio N, Ben-Omran T, Teebi A, Ha KCH, Lalonde E , Ali R, Almureikhi M, Der Kaloustian VM, Liu J, **Rosenblatt, DS**, Majewski J, Jerome-Majewska LA. Mutations in SCARF2 are Responsible for Van Den Ende-Gupta Syndrome. *Amer J Hum Genet*, 87, 553–559, 2010

--Plesa M, Kim J, Paquette SG, Gagnon H, Ng-Thow-Hing C, Gibbs BF, Hancock MA, **Rosenblatt DS**, Coulton JW. Interaction between MMACHC and MMADHC, two human proteins participating in intracellular vitamin B12 metabolism. *Molec Genet Metab*, 102:139-

148, 2010

Rudski, Lawrence

--**Rudski LG**, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB: Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. *Journal of the American Society of Echocardiography* 23:685-713, 2010

Schiffrin, Ernesto

--Grassi G, Seravalle G, Brambilla G, Dell'Oro R, Fattori L, Quarti-Trevano F, Bolla GB, Mozzi E, **Schiffrin EL**, Mancina G. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. *Obesity*, 18:92–98, 2010

--Savoia C, Ebrahimian T, Lemarié CA, Iglarz M, Amiri F, Javeshgani D, **Schiffrin EL**. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: Role of oxidative stress and PRMT-1. *Clin Sci*, 118:583-592, 2010

--**Schiffrin EL**. T lymphocytes: A role in hypertension? Invited review. *Current Opinion in Nephrol Hypertension*, 19:181–186, 2010

--Lemarié CA, **Schiffrin EL**. Angiotensin II type 2 receptor in cardiovascular disease. *J Renin Ang Aldo System*. 11:19-31, 2010

--Viel EC, Lemarié CA, Benkirane K, Paradis P, **Schiffrin EL**. Immune regulation and vascular inflammation in genetic hypertension. *Amer J Physiol Heart Circ Physiol*, 298:H938-H944, 2010

--Fagard RH, Grassi G, Hall J, Harrap S, Lindholm LH, **Schiffrin EL**, Heagerty AM. International Society of Hypertension Low and Middle Income Countries Committee: Review of the Goals of the Committee and of 5 years of ISH activities in Low and Middle Income Countries. *J Hypertens*, 28:635–636, 2010

--Briet M and **Schiffrin EL**. Aldosterone effects on the kidney and cardiovascular system, and clinical value of aldosterone antagonism. *Nature Reviews Nephrology*, 6:261–273, 2010

--Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, **Schiffrin EL**. Deleterious combined effects of aging, salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function. *J Hypertens*, 28:1243-1251, 2010

--**Schiffrin EL**. How are stressed prehypertensive rats pressured? Endothelin pleads guilty. Editorial Commentary. *Hypertension*, 56:191-192, 2010

--Rehman A, **Schiffrin EL**. Vascular Effects of Antihypertensive Drug Therapy. *Curr Hypertens Rep*, 12:226-232, 2010

--Grassi G, **Schiffrin EL**. Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions. Editorial Commentary. *J Hypertens*, 28:1811-1813,

2010

--Leenen FH, **Schiffrin EL**. Control rates of Hypertension in North America. Editorial. Hypertension, 56:571-572, 2010

--**Schiffrin EL**. Circulatory Therapeutics: Use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med, 14:1018–1029, 2010

--Motillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, **Schiffrin EL**, Eisenberg M J. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. J Amer Coll Cardiol, 56:1113-1132, 2010

--Bouchentouf M, Forner KA, Cuerquis J, Michaud V, Zheng J, Paradis P, Boulassel MR, Routy JP, **Schiffrin EL**, Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and $\alpha 4\beta 7$ integrin expression by NK cells. J Immunol, 185:7014-25, 2010 Epub 2010 Oct 22. PMID: 20971926, 2010

--Ducharme A, **Schiffrin EL**. Reviewing the future of RAS blockade: The role of ACE inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. Can J Cardiol, 26(Suppl E):21E-23E, 2010

--**Schiffrin EL**. Antioxidants in hypertension and cardiovascular disease. Mol Interventions. 10:354-62, 2010

--Bouchentouf M, Paradis P, Forner KA, Cuerquis J, Boivin MN, Zheng J, Boulassel MR, Routy JP, **Schiffrin EL**, Galipeau J. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant, 19:369-86, 2010

--Simeone SMC, Melissa W. Li, Paradis P, **Schiffrin EL**. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics, 43:148-160, 2010

--Mann JFE, **Schiffrin EL**. Ch. 69, Renal Dysfunction in "Evidence based Cardiology", 3rd Edition, Ed. S Yusuf, JA Cairns, AJ Camm, EL Fallen, BJ Gersh. Blackwell Publishing, pp 1110-1117, 2010

Schipper, Hyman

--Al-Hashmi A, Nguyen OF, Glikstein RS, **Schipper HM**. Cerebral venous thrombosis presenting as subacute parkinsonism. Can J Neurol Sci, 37:684-686, 2010

--Maes OC, **Schipper HM**, *Chong G, **Chertkow HM**, Wang E: A GSTM3 polymorphism associated with an etiopathogenetic mechanism in Alzheimer disease. Neurobiology of Aging, 31:34-45, 2010

Schweitzer, Morris

--**Schweitzer M**, Mitmaker B, Obrand D, Sheiner N, Abraham C, Dostanic S, Meilleur M,

Sugahara T, Chalifour LE: Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. *Vascular and Endovascular Surgery*, 44:116-122, 2010

Sebag, Igal

--Chan KL, Teo K, Dumesnil JG, Ni A, Tam J and for the ASTRONOMER Investigators including **Sebag I**. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation*, 121:306-314, 2010

Sheppard, Richard

--**Sheppard R**: Vascular tone and the genomics of hypertension. *Heart Failure Clinics*, 6:45-53, 2010

Small, Peter

--Wasserman S, Chad Z, Francoeur MJ, **Small P**, Stark D, Vander Leek TK, Kaplan A, Kastner M. Management of anaphylaxis in primary care: Canadian expert consensus recommendations. *Allergy*, 65:1082-1092, 2010

Suissa, Samy

-- Klein R, Myers CE, Klein BE, Zinman B, Gardiner R, **Suissa S**, Sinaiko AR, Donnelly SM, Goodyer P, Strand T, Mauer M. Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. *Arch Ophthalmol*, 128:198-205, 2010

--Gonzalez AV, Li G, **Suissa S**, **Ernst P**. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. *Pulm Pharmacol Ther*, 23:65-70, 2010

-- Azoulay L, Schneider-Linder V, Dell'aniello S, Schiffrin A, **Suissa S**. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. *Pharmacoepidemiol Drug Saf*, 19:335-342, 2010

-- Azoulay L, Schneider-Linder V, Dell'aniello S, Fillion KB, **Suissa S**. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. *Pharmacoepidemiol Drug Saf*, 19:343-350, 2010

-- Simon TA, Askling J, Lacaille D, Franklin J, Wolfe F, Covucci A, **Suissa S**, Hochberg MC; the Abatacept Epidemiology Study Group. *Arthritis Res Ther*, 12:R67, 2010

-- **Suissa S**. Co-morbidity in COPD: the effects of cardiovascular drug therapies. *Respiration*, 80:3-7, 2010

-- Hudson M, **Suissa S**. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. *Arthritis Care Res (Hoboken)*, 62:805-810, 2010

-- Klein R, Knudston MD, Klein BE, Zinman B, Gardiner R, **Suissa S**, Sinaiko AR, Donnelly SM, Goodyear P, Strand T, Mauer M. The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes. *Diabetologia*, 553:1638-1646, 2010

-- Renoux C, Dell'aniello S, **Suissa S**. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. *J Thromb Haemost*, 8:979-986, 2010

-- Bernatsky S, Renoux C, **Suissa S**. Demyelinating events in rheumatoid arthritis after drug exposures. *Ann Rheum Dis*, 69:1691-1693, 2010

-- Martinez C, Assimes TL, Mines D, Dell'Aniello S, **Suissa S**. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. *BMJ*, 340:c249 doi: 10.1136/bmj.c249], 2010

-- Lévesque LE, Hanley JA, Kezouh A, **Suissa S**. Problem of immortal time bias in cohort studies : example using statins for preventing progression of diabetes. *BMJ*, 340:b5087, 2010

-- McLaughlin VV, **Suissa S**. [Editorial] Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. *Circulation*, 122:106-108, 2010

-- Renoux C, Dell'aniello S, Garbe E, **Suissa S**. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. *BMJ*, 340:c2519, 2010

-- **Suissa S**, Dell'Aniello S, Martinez C. The multitime case-control design for time-varying exposures. *Epidemiology*, 21:876-83, 2010

-- **Suissa S**, Kezouh A, **Ernst P**. Inhaled corticosteroids and the risk of diabetes onset and progression. *Am J Med*, 123:1001-6, 2010

Szilagyi, Andrew

-- Heilpern D, Abbas RN, Gladman S, Menard M, Lee BH, **Szilagyi A**. High fructose intake fails to induce symptomatic adaptation but may induce intestinal carriers. *Gastroenterology Insights*. <http://www.pagepress.org/gi>, 2:e3, 2010.

--**Szilagyi A**: Determinants of geographic patterns of diseases: Interaction of lactose/lactase status and sunshine exposure. *Medical Hypotheses*. 75:466-470, 2010

--**Szilagyi A**, *Shrier I, Heilpern D, Je J, Park S, **Chong G**, Lalonde C, Cote LF, Lee B: Differential impact of lactose/lactase phenotype on colonic microflora. *Canadian Journal of Gastroenterology* 24:373-379. 2010

Tagalakis, Vicky

--Robinson-Cohen C, Pilon D, Dubois MF, **Tagalakis V** . An assessment of surgical thromboprophylaxis in a tertiary care center. *Clinical and Applied Thrombosis/Hemostasis*, 1-7, 2010

--**Tagalakis V**, Tamim H. The effect of warfarin use on clinical stage and histological grade of prostate cancer. *Pharmacoepidemiology and Drug Safety*, 19:436–439, 2010

Tischkowitz, Marc

--**Tischkowitz MD** and Bing Xia. PALB2/FANCN - recombining cancer and Fanconi anemia *Cancer Research*, 70(19):7353-9, 2010

--Al Fares A, Millington GWM, **Tischkowitz MD**. Dermatological features of inherited cancer syndromes in adults *Clinical and Experimental Dermatology*, 35:462-7, 2010

--McQuirter M, Castiglia LL, Loiselle CG, **Wong N**. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy. *Oncol Nurs Forum*. 37:313-20, 2010

--Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, **Tischkowitz M**, Sabbaghian N, Apicella C, Byrnes GB, Winship I, Cancer Family Registry B, Confab K, Baglietto L, Giles GG, Goldgar D, **Foulkes WD**, Hopper JL. A PALB2 mutation associated with high risk of breast cancer. *Breast Cancer Res*. 12:R109, 2010 (early online publication)

--Rio Frio T, Haanpää M, Pouchet C, Pylkäs K, Vuorela M, **Tischkowitz M**, Winqvist R, **Foulkes WD**. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families. *J Hum Genet*, 55:842-3, 2010

Therrien, Judith

--Bernier, M, Marelli A, Pilote L, Bouchardy J, Martucci G, **Therrien J**. Atrial Arrhythmias in Adults with Left vs Right Congenital Heart Disease. *Am J Card*, 106:547-551, 2010

--Owens CG, **Therrien J**, Kotowycz MA, Martucci G, Ionescu RI, Pilote L, Dancea A, Tchervenkov C, Marelli AJ. Long Term Follow-up of Children Undergoing Transcatheter vs Surgical Closure of Atrial Septal Defect. A Population Based Study. *Canadian Journal of Cardiology*, 26 (Supp D), 2010

--**Therrien J**. Chapter 4. LVOT obstruction. *American College of Cardiology Echo SAP6*, 2010

--Marelli A, Beauchesne L, Mital S, **Therrien J**, Silversides CK. Canadian Cardiovascular Society Consensus conference on Management of Adults with Congenital Heart Disease. Introduction. *Can J Cardiol*, 26:e65-e69, 2010

--Silversides CK, Dore A, Porier N, Taylor D, Harris L, Greutmann B, Benson L, Baumgartner H, Celermajer D, **Therrien J**. Canadian Cardiovascular Society 2009 Consensus conference on the Management of Adults with Congenital Heart Disease: Shunt Lesions. *Can J Cardiol*, 26:e70-e79, 2010

--Silversides CK, Kiess M, Beauchesne L, Bradley T, Connelly M, Niwa K, Mulder B, Webb G,

Colman J, **Therrien J**. Canadian Cardiovascular Society 2009 Consensus Conference on the Management of Adults with Congenital Heart Disease: Outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan syndrome. *Can J Cardiol*, 26:e80-e97, 2010

--Siversides CK, Salehian O, Oechslin E, Schwerzmann M, Vonder Muhil I, Khiary P, Horlick E, Landzberg M, Meijboom F, Warnes C, **Therrien J**. J Canadian Cardiovascular Society 2009 Consensus Conference on the Management of Adults with Congenital Heart Disease: Complex congenital cardiac lesions. *Can J Cardiol*, 26:e98-e117, 2010

--Owens CG, **Therrien J**, Kotowycz MA, Martucci G, Ionescu RI, Pilote L, Dancea A, Tchervenkov C, Marelli AJ. Long Term Safety of Children Undergoing Transcatheter vs Surgical Closure of Atrial Septal Defect. A Population Based Study. *Circulation*, 122:A21439, 2010

--Kotowycz MA, **Therrien J**, Ionescu-Ittu R, Owens C, Martucci G, Tchervenkov C, Marelli AJ. Long-Term Outcomes After Surgical vs Transcatheter Closure of Atrial Septal Defects in Adults. *AHA* 2010. *Circulation*, 122:A17482, 2010

Thombs, Brett

--Schieir O, **Thombs BD**, Hudson M, Boivin JF, Steele R, Bernatsky S, Hanley J, Baron M. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. *Arthritis Care Res (Hoboken)*, 62:409-17, 2010

--**Thombs BD**, van Lankveld W, Bassel M, **Baron M**, Buzza R, Haslam S, Haythornthwaite JA, Hudson M, Jewett LR, Knafo R, Kwakkenbos L, Malcarne VL, Milette K, Motivala SJ, Newton EG, Nielson WR, Pacy M, Razykov I, Schieir O, Taillefer S, Worron-Sauve M. Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. *Arthritis Care Res (Hoboken)*, 62:1181-9, 2010

--Eze-Nliam CM, **Thombs BD**, Lima BB, Smith CG, Ziegelstein RC: The association of depression with adherence to antihypertensive medications: a systematic review. *Journal of Hypertension*, 28:1785-1795, 2010

--Parakh K, Bhat U, Thombs BD, Fauerbach JA, Bush DE, Ziegelstein RC: Self-assessed physical health predicts 10-year mortality after myocardial infarction. *Journal of Cardiopulmonary Rehabilitation and Prevention*, 30:35-39, 2010

--***Thombs BD**, van Lankveld W, Bassel M, **Baron M**, Buzza R, Haslam S, Haythornthwaite JA, Hudson M, Jewett LR, Knafo R, Kwakkenbos L, Malcarne VL, Milette K, Motivala SJ, Newton EG, Nielson WR, Pacy M, Razykov I, Schieir O, Taillefer S, Worron-Sauve M: Psychological health and well-being in systemic sclerosis: state of the science and consensus research agenda. *Arthritis Care & Research (Hoboken)*, 62:1181-1189, 2010

Warshawsky Paul

--Levinoff EJ, **Warshawsky PW**, Kahn SR. Fatal bilateral adrenal hemorrhage after

thrombolytic therapy for venous thromboembolism. Canadian Journal of General Internal Medicine, 5:114-115, 2010

Wassmann, Sven

--Steinmetz M, Brouwers C, Nickenig G, **Wassmann S**: Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 14:1645-1656, 2010

--Mueller CF, Afzal S, Becher UM, Wassmann S, Nickenig G, Wassmann K: Role of the multidrug resistance protein-1 (MRP1) for endothelial progenitor cell function and survival. Journal of Molecular and Cellular Cardiology, 49:482-489, 2010

--Mueller CF, Becher MU, Zimmer S, **Wassmann S**, Keuler B, Nickenig G: Angiotensin II triggers release of leukotriene C(4) in vascular smooth muscle cells via the multidrug resistance-related protein 1. Molecular and Cellular Biochemistry, 333:261-267, 2010

--Tiyerili V, Zimmer S, Jung S, Wassmann K, Naehle CP, Lütjohann D, Zimmer A, Nickenig G, Wassmann S: CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Research in Cardiology, 105:465-477, 2010

--Wassmann K, Mueller CF, Becher UM, Werner C, Jung A, Zimmer S, Steinmetz M, Nickenig G, **Wassmann S**: Interaction of inhibitor of DNA binding 3 (Id3) with Gut-enriched Krüppel-like factor (GKLF) and p53 regulates proliferation of vascular smooth muscle cells. Molecular and Cellular Biochemistry, 333:33-39, 2010

7. APPENDIX A. DIVISIONAL REPORTS